The Lauber family built its wealth in real estate, and that’s where it stayed for decades. But, lately, some of the family money has a buzzy new destination: biotech.
“I’m kind of like a hypochondriac,” says Robin Lauber, the third-generation heir who is diversifying the Swiss family’s wealth, mainly into companies working in cutting-edge biology. Lauber, 30, is particularly interested in longevity medicine, a nascent strand of research that aims to slow down the ageing process.
“I want to continue living as long as possible,” he says, pointing out that there are other animal species that have a lifespan of as long as 200 years.
您已閱讀4%（635字），剩余96%（13974字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。